Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2026
    • The 2026 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Educational Assets
    • Manufacturer Search
    • Podcasts
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Views
    • Video
  • 2026 Leadership
    • 2025 Winners
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • Subscribe

Biodesix Receives New EU and US Patents for Blood-based Oncology Tests

January 10, 2012 By AxoGen, Inc.

BROOMFIELD,
Colo.–(BUSINESS WIRE)–Biodesix, Inc., a fully integrated molecular diagnostics
company dedicated to personalizing medicine, today announced the issuance of
three additional patents. The U.S. Patent & Trademark Office (PTO) granted
two new patents which provide intellectual property protection for methods
relating to the Companys products and technology. In addition, the European Patent Office granted
to Biodesix a patent providing coverage for the Companys product VeriStrat®, for the selection of patients for drug therapy.
VeriStrat is a serum proteomic test currently available in the United States
to help physicians guide therapy for patients with advanced lung cancer.

European patent number 2,247,954 is the counterpart to U.S. patent
number 7,867,775 and covers the use of VeriStrat for selection of head and neck
cancer patients for treatment with targeted drugs. U. S. patent number
8,024,282 (‘282) provides additional intellectual property protection for the
methods used with VeriStrat which are also related to Biodesix underlying core
ProTS® technology. Specifically, the ‘282 patent supports the Companys methods
for the reliable and reproducible classification of samples in clinical
diagnostics using computer systems configured as probabilistic classifiers.
Related U.S. patent 7,906,342 covers Biodesix methods for using mass
spectrometry of patient samples to monitor cancer patients being treated with
drugs targeting the epidermal growth factor receptor (EGFR) pathway for response
or non-responsiveness to the treatment. Biodesix also received notice from the
PTO that two additional patent applications covering the use of VeriStrat for
monitoring of head and neck, as well as colorectal cancer patients being
treated with drugs targeting the EGFR pathway have been allowed; these patents
are expected to issue early in the first quarter of 2012.

Drug therapies targeting the EGFR pathway and related
molecular targets play an increasingly important role in cancer therapy.
Identifying patients likely to benefit from this class of drugs is key to
improving overall patient outcomes.

“The expansion of our patent estate is an integral part of
our global strategy to protect VeriStrat and our technology platform,”
commented David Brunel, Biodesix CEO. “This protection strengthens our
commercial position as a leading provider of diagnostics to personalize
medicine for oncology patients.”

About Biodesix

Biodesix is a fully integrated molecular diagnostics company advancing the
development of products for personalized medicine. Biodesix provides physicians
with tools for earlier disease detection, more accurate diagnosis, and better
therapeutic guidance. In 2009, Biodesix launched VeriStrat®, a serum proteomic
test that helps physicians guide treatment for patients with non-small cell
lung cancer. VeriStrat is based on ProTS®, proprietary technology which
harnesses the power of mass spectrometry and enables the discovery of specific
molecular profiles that characterize a patients condition or likely outcome in
response to therapy. The ProTS® platform has broad application and provides the
foundation for collaborations with leading researchers as well as partnerships
with biotechnology and pharmaceutical companies seeking to develop companion diagnostics
and improve the targeting of their therapies. For more information about
Biodesix, please visit the Companys website at www.Biodesix.com.

Posted by Sean Fenske, Editor-in-Chief, MDT

Related Articles Read More >

An illustration showing the Autus size-adjustable heart valve being expanded years after implantation with a minimally invasive balloon catheter.
The first-of-its-kind Autus pediatric heart valve is designed for expansion and durability
The MIT researcher's implant, LUCID.
MIT researchers design implantable ultrasound-powered drug delivery device to minimize tumor recurrence
An image of the Teleflex Freesolve RMS resorbable magnesium scaffold.
Teleflex Interventional leader sees resorbables as ‘the next frontier’ of PCI
Feminai's breast sensor patch
AdvaMed and MedTech Innovator name 2026 prize winners and finalists
“mdo
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest medical device business news, application and technology trends.

DeviceTalks Weekly

See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

New MedTech Resource

Medical Tubing

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech100 Index
  • Medical Tubing + Extrusion
  • Medical Design Sourcing
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to our E-Newsletter
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2026 Arrowfly, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2026
    • The 2026 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Educational Assets
    • Manufacturer Search
    • Podcasts
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Views
    • Video
  • 2026 Leadership
    • 2025 Winners
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • Subscribe